Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals Misses on Revenue, Stock Down 1.17%

Alnylam Pharmaceuticals reported a wider-than-expected loss per share, but there was no revenue figure to assess performance fully. The stock reacted by declining 1.17%, indicating some investor concern despite the slight EPS beat. Without additional context from management commentary, the outlook remains unclear.